

## **UTILITY PATENT APPLICATION TRANSMITTAL**

(only for new non-provisional applications under 37 CFR §1.53(b))

17548 U.S. PTO 10/789017

Mail Stop Patent Application Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Transmitted herewith for filing is the patent application under 37 CFR 1.53(b) of:

AVENTIS DOCKET NO.: DEAV2003/0019 US NP

INVENTORS: Christian Stapper, et al

TITLE:

Arylcycloalkyl-Substituted Alkanoic Acid

Derivatives, Processes For Their Preparation And Their Use As

**Pharmaceuticals** 

I hereby certify that this correspondence is being
deposited with the United States Postal Service a
Express Mail in an envelope addressed to Mail Stor
Patent Application, Commissioner for Patents, P.O.
Box 1450, Alexandria, VA 22313-1450, on
11/17 1011
V/ d +/U4
Date of Deposit
MIN I MINI D
11 1110 1011 1110000

EL964822471US

Express Mail No.

APPI	IC A	TION	=ME	NTC

1.	$\boxtimes$	*Fee Transmittal Form (e.g., PTO/SB/17) (Submit an original and a duplicate for fee processing)		
2.		Specification (preferred arrangement set forth below) - Descriptive title of the Invention - Cross References to Related Applications - Statement Regarding Fed sponsored R & D - Reference to Microfiche Appendix - Background of the Invention - Brief Summary of the Invention - Brief Description of the Drawings (if filed) - Detailed Description - Claim(s) - Abstract of the Disclosure	Total Pages	150
3.		Drawing(s) (35 U.S.C. 113)	Total Sheets	
4.	Oath a.	or Declaration  Unexecuted (original or copy)	Total Pages	2
	b.	Copy from a prior application (37 CFR § 1.	.63(d))	
		i. DELETION OF INVENTOR(S)  Signed statement attached deleting i application, see 37 CFR §§ 1.63(d)(2)		ned in the prior
5.	Powe	er of Attorney	Total Pages	
	a.	Newly executed (original or copy)		
	b.	Copy from a prior application (37 CFR § 1.	63(d))	
6.		Microfiche Computer Program (Appendix)		

Appli	cation Transmittal Letter 2
7.	Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)  a. Computer Readable Copy  b. Paper Copy (identical to computer copy)
	c. Statement verifying identity of above copies
	If a CONTINUING Application, check appropriate box, and supply the requisite information:  Continuation Divisional Continuation-in-part of prior application no: , filed , Examiner, Group/Art Unit (The cross reference has been/will be inserted on page one of the specification).
	This application claims the benefit of U.S. Provisional Application No. 60/487,510, filed July 15, 2003, and claims priority of German Application No. 10308355.3 filed February 27, 2003.  (The cross reference has been/will be inserted on page one of the specification).
	Incorporation By Reference (useable if filing a continuation/divisional and a copy of the declaration from the prior application is enclosed.)  The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.
ACC	OMPANYING APPLICATION PARTS
7.	Assignment Papers (cover sheet & document(s))
8.	37 CFR §3.73(b) Statement
9.	(when there is an assignee)  Verified English Translation Document (if applicable)
10.	Information Disclosure Copies of IDS Citations
	Statement (IDS)/PTO-1449
11.	Preliminary Amendment
12.	Return Receipt Postcard (MPEP 503)
13.	(Should be specifically itemized)  *Small Entity Statement(s)  Statement filed in prior application,
13.	(PTO/SB/09-12) Status still proper and desired
14.	Certified Copy of Priority Document(s) 10308355.3
15.	(if foreign priority is claimed)  Other: Application Data Sheet (6 pgs.)
COR	RESPONDENCE ADDRESS
$\boxtimes$	Customer Number or Bar Code Label 005487
	(Insert Customer No. or Attach bar code label here)
	Dabare E. Kong
	Barbara E. Kurys, Reg. No. 34,650

Barbara E. Kurys, Reg. No. 34,650 Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, New Jersey 08807-0800
Telephone (908) 231-2965
Telefax (908) 231-2626
Aventis Docket No. DEAV2003/0019 US NP

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

FEE TRANSMITTAL		Complete if Known			
LEE IKANOMIIIAL	Application Number	Not Yet Assigned			
C F\/ 0004	Filing Date	Concurrently Filed Herewith			
for FY 2004	First Named Inventor	Christian Stapper, et al			
Patent fees are subject to annual revision.	Examiner Name				
Applicant claims small entity status. See 37 CFR 1.27	Group / Art Unit				
TOTAL AMOUNT OF DAYMENT (C) 770.00	Attorney Docket No.	DEAV/2003/0049 HS ND			

METHO	D OF PAYMENT	(check all that apply)	FEE CALCUL			E CAL	CULATION (continued)	
Check	Credit Card Mon-		3. ADDITIONAL FEES			EES		
Order			Large E		Small E	-		
Deposit Account	10	-1982	Fee Code	Fee (\$)	Fee Code	Fee (\$)		
Number Deposit		-1902		,		,	Fee Description	Fee Paid
Account Name	Aventis Phar	maceuticals Inc.	1051	130	2051	65	Surcharge - late filing fee or oath	
		: (check all that apply)					Surcharge - late provisional filing fee or	
, —	s) indicated below	Credit any overpayments	1052 1053	50 130	2052 1053	25 130	cover sheet Non-English Specification	
Charge any	additional fee(s) during th	e pendency of this application	1812	2,520	1812	2,520	For filing a request for reexamination	
	s) indicated below, excepte-identified deposit account		1804	920*	1804	920*	Requesting publication of SIR prior to Examiner action	
	FEE CALCULA		1805	1,840*	1805	1,840*	Requesting publication of SIR after Examiner action	
1. BASIC FI			1251	110	2251	55	Extension for reply within first month	
Large Entity Fee Fee	Small Entity Fee Fee Fee I	Fee Description Paid	1252	420	2252	205	Extension for reply within second month	
Code (\$)	Code (\$)						• •	<u> </u>
1001 770	•	filing fee 770	1253	950	2253	465	Extension for reply within third month	
1002 340 1003 530	<del>-</del>	n filing Fee filing fee	1254 1255	· 1,480 2,010	2254 2255	725 985	Extension for reply within fourth month  Extension for reply within fifth month	
1003 330		sue filing fee	1401	330	2401	160	Notice of Appeal	<u> </u>
1005 160		sional filing fee	1402	330	2402	160	· ·	
			1402	290	2402	140	Filing a brief in support of an appeal  Request for oral hearing	
	SUBTOTAL (1)	(\$) 770.00	_					
2. EXTRA C	LAIM FEES FOR U	TILITY AND REISSUE	1451	1,510	1451	1,510	Petition to institute a public use proceeding	
	Extra	Fee from Fee	1452	110	2452	55	Petition to revive - unavoidable	
ا	Claims	below Paid	1					
Total Claims 1	5 -20**= -0-	x 18 = -0-	1453	1,330	2453	650	Petition to revive - unintentional	
Independent 1	- 3**= -0-	x 86 = -0-	1501	1,330	2501	650	Utility issue fee (or reissue)	
Claims			1502	480	2502	235	Design issue fee	
Multiple Depende	nt	=	1503	640	2503	315	Plant issue fee	
Large Entity	Small Entity		1460 1807	130 50	1460 1807	130 50	Petitions to the Commissioner Petitions related to provisional	
Fee Fee	Fee Fee		1007	30	1007	30	applications	
Code (\$)		Description	1806	180	1806	180	Submission of Information Disclosure	
1202 18		s in excess of 20					Stmt	
1201 86	2201 42 Indep	endent claims in excess of 3	8021	40	8021	40	Recording each patent assignment per property (times number of properties)	
1203 290	2203 140 Multip paid	ole dependent claim, if not	1809	770	2809	375	Filing a submission after final rejection (37 CFR § 1.129(a))	
1204 86	2204 42 **Rei	ssue independent ms over original patent	1810	770	2810	375	For each additional invention to be examined (37 CFR § 1.129(b))	
1205 18	2205 9 **Rei	ssue claims in excess of and over original patent	1801	770	2801	375	Request for Continued Examination (RCE)	
	Þ		1802	900	1802	900	Request for expedited examination of a design application	
SUBTOTAL (2) (\$)0.00			Other fee	(specify)				
**or number previously paid, if greater; For Reissues, see above			*Reduce	d by Basic	Filing Fee	Paid	SUBTOTAL (3) (\$)	

SUBMITTED BY			Complete (If applicable)		
Name (Print/Type)	Barbara E. Kurys, Reg. No. 34,650	Registration No. (Attorney/Agent)	34,650	Telephone	(908) 231-2965
Signature	Barban E. Kenn			Date	2/27/2004

WARNING: Information on this form may become public. Credit card information should not be

included on this form. Provide credit card information on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Alexandria, VA 22313. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313.1450 VA 22313-1450.